Product Details
| Product Name:
PYZD-4409 |
CAS No.:
423148-78-1 |
| Purity:
98.00% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | PYZD-4409 |
| Description | PYZD-4409 is a selective UBA1 inhibitor with an IC50 of 20 μM. PYZD-4409 induces cell death in malignant cells and is preferentially cytotoxic to malignant cells over normal hematopoietic cells. |
| In vitro | PYZD-4409 is preferentially cytotoxic to malignant cells over normal hematopoietic cells. PYZD-4409 increases levels of phospho-JNK and phospho-p38 mitogen-activated protein kinase, which have also been linked to ER stress and the unfolded protein response. PYZD-4409 (50 μM; 4 hours; K562 leukemia cells) treatment blocks the E1-dependent conjugation of ubiquitin to the E2 enzyme cdc34. PYZD-4409 (0-25 μM; 24 hours; K562 leukemia cells) significantly increases both mRNA and protein levels of Grp78 and Hsp70. PYZD-4409 (10-40 μM; 72 hours; myeloma, leukemia, and solid tumor cell lines, primary AML cells and normal hematopoietic cells) induces cell death with an LD50 less than 10 μM in 5 of 8 leukemia and myeloma cell lines. Solid tumor cell lines were less sensitive with an LD50 of approximately 15 to 20 μM [1]. |
| In vivo | PYZD-4409 (10 mg/kg; intraperitoneal injection; administered every other day for 16 days; male severe combined immunodeficient mice) reduces tumor weight and volume[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 6 mg/mL (17.06 mM), Sonication is recommended.
|
| Keywords | PYZD4409 | Inhibitor | E3 ligating enzyme | E2 conjugating enzyme | inhibit | E1/E2/E3 Enzyme | Ubiquitin activating enzyme | E1 activating enzyme | Ubiquitin ligase | Ubiquitin conjugating enzyme | PYZD 4409 | PYZD-4409 |
| Inhibitors Related | NSC697923 | WS-383 | Nutlin-3 | NAcM-OPT | RG7112 | PYR-41 | BC-1382 | NSC232003 | NAE-IN-M22 | Indole-3-carbinol | Idasanutlin | Navtemadlin |
| Related Compound Libraries | Bioactive Compound Library | Ubiquitination Compound Library | Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1207745-58-1
$293.00 / 1mg
-
CAS:667463-82-3
$39.00 / 1mg
-
CAS:23981-47-7
$40.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States